• español
  • English
  • français
  • Deutsch
  • português (Brasil)
  • italiano
    • español
    • English
    • français
    • Deutsch
    • português (Brasil)
    • italiano
    • español
    • English
    • français
    • Deutsch
    • português (Brasil)
    • italiano
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Listar

    Todo UVaDOCComunidadesPor fecha de publicaciónAutoresMateriasTítulos

    Mi cuenta

    Acceder

    Estadísticas

    Ver Estadísticas de uso

    Compartir

    Ver ítem 
    •   UVaDOC Principal
    • PRODUCCIÓN CIENTÍFICA
    • Departamentos
    • Dpto. Biología Celular, Genética, Histología y Farmacología
    • DEP05 - Artículos de revista
    • Ver ítem
    •   UVaDOC Principal
    • PRODUCCIÓN CIENTÍFICA
    • Departamentos
    • Dpto. Biología Celular, Genética, Histología y Farmacología
    • DEP05 - Artículos de revista
    • Ver ítem
    • español
    • English
    • français
    • Deutsch
    • português (Brasil)
    • italiano

    Exportar

    RISMendeleyRefworksZotero
    • edm
    • marc
    • xoai
    • qdc
    • ore
    • ese
    • dim
    • uketd_dc
    • oai_dc
    • etdms
    • rdf
    • mods
    • mets
    • didl
    • premis

    Citas

    Por favor, use este identificador para citar o enlazar este ítem:http://uvadoc.uva.es/handle/10324/46162

    Título
    Subconjunctival injection of mesenchymal stem cells for corneal failure due to limbal stem cell deficiency: state of the art
    Autor
    Galindo de la Rosa, SaraAutoridad UVA Orcid
    De La Mata Sampedro, AnaAutoridad UVA Orcid
    López Paniagua, MarinaAutoridad UVA Orcid
    Herreras Cantalapiedra, José MaríaAutoridad UVA Orcid
    Pérez Soto, María InmaculadaAutoridad UVA
    Calonge, MargaritaAutoridad UVA Orcid
    Nieto Miguel, TeresaAutoridad UVA Orcid
    Año del Documento
    2021
    Editorial
    BioMed Central. Springer Nature
    Descripción
    Producción Científica
    Documento Fuente
    Stem Cell Research & Therapy, 2021, vol. 12, 60
    Resumen
    Mesenchymal stem cells (MSCs) have unique and beneficial properties and are currently used to treat a broad variety of diseases. These properties include the potential for differentiation into other cell types, secretion of different trophic factors that promote a regenerative microenvironment, anti-inflammatory actions, selective migration to damaged tissues, and non-immunogenicity. MSCs are effective for the treatment of ocular surface diseases such as dry eye, corneal burns, and limbal stem cell deficiency (LSCD), both in experimental models and in humans. LSCD is a pathological condition in which damage occurs to the limbal epithelial stem cells, or their niche, that are responsible for the continuous regeneration of the corneal epithelium. If LSCD is extensive and/or severe, it usually causes corneal epithelial defects, ulceration, and conjunctival overgrowth of the cornea. These changes can result in neovascularization and corneal opacity, severe inflammation, pain, and visual loss. The effectiveness of MSCs to reduce corneal opacity, neovascularization, and inflammation has been widely studied in different experimental models of LSCD and in some clinical trials; however, the methodological disparity used in the different studies makes it hard to compare outcomes among them. In this regard, the MSC route of administration used to treat LSCD and other ocular surface diseases is an important factor. It should be efficient, minimally invasive, and safe. So far, intravenous and intraperitoneal injections, topical administration, and MSC transplantation using carrier substrata like amniotic membrane (AM), fibrin, or synthetic biopolymers have been the most commonly used administration routes in experimental models. However, systemic administration carries the risk of potential side effects and transplantation requires surgical procedures that could complicate the process. Alternatively, subconjunctival injection is a minimally invasive and straightforward technique frequently used in ophthalmology. It enables performance of local treatments using high cell doses. In this review, we provide an overview of the current status of MSC administration by subconjunctival injection, analyzing the convenience, safety, and efficacy for treatment of corneal failure due to LSCD in different experimental models. We also provide a summary of the clinical trials that have been completed, are in progress, or being planned.
    Materias Unesco
    3201.09 Oftalmología
    Palabras Clave
    Subconjunctival injection
    Cornea
    Limbus
    Regeneration
    Mesenchymal stem cells
    Limbal stem cell deficiency
    Corneal epithelium
    ISSN
    1757-6512
    Revisión por pares
    SI
    DOI
    10.1186/s13287-020-02129-0
    Patrocinador
    Consejería de Educación, Junta de Castilla y León (Proyecto VA268P18 FEDER, EU); Ministerio de Ciencia e Innovación (Proyecto PID2019-105525RB-100, MICINN/FEDER);Instituto de Saludo Carlos III, CIBER-BBN (CB06/01/003 MICINN/FEDER, EU); Centro en Red de Medicina Regenerativa y Terapia Celular de Castilla y León.
    Version del Editor
    https://stemcellres.biomedcentral.com/articles/10.1186/s13287-020-02129-0
    Propietario de los Derechos
    © The Author(s), 2021
    Idioma
    eng
    URI
    http://uvadoc.uva.es/handle/10324/46162
    Tipo de versión
    info:eu-repo/semantics/publishedVersion
    Derechos
    openAccess
    Aparece en las colecciones
    • IOBA - Artículos de revista [80]
    • DEP05 - Artículos de revista [198]
    Mostrar el registro completo del ítem
    Ficheros en el ítem
    Nombre:
    2021 Galindo_et_al-Stem_Cell_Research_&_Therapy_Subconjunctival injection of MSC for LSCD.pdf
    Tamaño:
    764.7Kb
    Formato:
    Adobe PDF
    Thumbnail
    Visualizar/Abrir
    Attribution-NonCommercial-NoDerivatives 4.0 InternacionalLa licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional

    Universidad de Valladolid

    Powered by MIT's. DSpace software, Version 5.10